Yesintek is the latest Stelara biosimilar to gain FDA approval and it will be available in February 2025.

If granted, Tremfya will be approved to treat children ages six and under with severe plaque psoriasis and children ages five ...

Seemal Desai, M.D., FAAD, discusses how managed care organizations can improve access to advanced vitiligo treatments through ...

In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting ...

Two industry-sponsored studies investiaged needs of people with pulmonary hypertesion and interstitial lung disease.

Paul Fronstin, director of Health Benefits Research at EBRI, discussed ERISA and trends in employer self-insurance during a ...

The Stanford medical school professor, the expected pick for the top job at the National Institutes of Health, has been a ...

New data suggests clinicians may be slower to recognize sepsis in people with pulmonary arterial hypertension.

Paul Fronstin, director of Health Benefits Research at EBRI, spoke with MHE about the challenges employers face in ...

Poor balance and coordination are prominent features of Friedreich’s ataxia (FRDA). Czech researchers found that neuropsychiatric symptoms are also common among patients with FRDA.